Peck Madigan Jones (on Behalf of Roivant Sciences, INC.)
Biopharmaceutical drug development.
Based in DC
🤖
AI Overview
With $0 in lobbying spend across 11 quarterly filings, Peck Madigan Jones (on Behalf of Roivant Sciences, INC.) is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2018 to 2020.
$0
Total Spend
3
Years Active
1
Firms Hired
1
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $0 |
| 2019 | $0 |
| 2020 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues
- •Issues related to healthcare, the Food and Drug Administration, and pharmaceuticals.
- •Issues related to drug development, Womens health issues
- •Issues pertaining to womens health and treatment of endometriosis; treatment of rare diseases; Issues related to the development of new treatments and therapies
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.